Department of Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
J Infect. 2018 Sep;77(3):242-248. doi: 10.1016/j.jinf.2018.05.011. Epub 2018 Jun 19.
Echinocandins are fungicidal and more active than fluconazole against Candida biofilms. This is known to be an important mechanism for Candida persistence. However, there is limited evidence of effectiveness of echinocandins for treating persistent candidemia.
We prospectively observed adult patients with persistent candidemia from March 2011 to February 2016. This was defined as the isolation of the same Candida species for ≥ 5 days from blood cultures. We used a time-dependent analysis to evaluate the impact of definitive therapy on mycological eradication and overall survival at 30 days from the index date (the date of collecting the second positive blood culture).
We screened 1162 episodes of candidemia. Of 196 non-duplicate patients enrolled, 64 received echinocandins and 132 received fluconazole as their first definitive therapy after the index date. The rates of mycological eradication and overall survival were 67.3% and 55.6%, respectively. The factors associated with mycological eradication included receipt of an echinocandin as the definitive therapy, adequate source control, and not receiving parenteral hyperalimentation. The factors related to overall survival were APACHE II, not receiving corticosteroids, and receiving cardiovascular or abdominal surgery.
Echinocandins were more effective than fluconazole in achieving mycological eradication in patients with persistent candidemia.
棘白菌素类药物具有杀真菌作用,并且比氟康唑更能有效对抗念珠菌生物膜,这是念珠菌持续存在的一个重要机制。然而,棘白菌素类药物治疗持续性念珠菌血症的有效性的证据有限。
我们前瞻性地观察了 2011 年 3 月至 2016 年 2 月期间患有持续性念珠菌血症的成年患者。这被定义为从血液培养物中分离出相同的念珠菌物种≥5 天。我们使用时间依赖性分析来评估明确治疗对 30 天(从第二次阳性血培养收集之日)索引日期的真菌学清除率和总生存率的影响。
我们筛选了 1162 例念珠菌血症发作。在纳入的 196 例非重复患者中,64 例接受棘白菌素类药物治疗,132 例接受氟康唑作为他们在索引日期后的首次明确治疗。真菌学清除率和总生存率分别为 67.3%和 55.6%。与真菌学清除相关的因素包括接受棘白菌素类药物作为明确治疗、充分的源头控制和不接受肠外高营养。与总生存率相关的因素包括急性生理和慢性健康评分 II、不接受皮质类固醇治疗和接受心血管或腹部手术。
在持续性念珠菌血症患者中,棘白菌素类药物比氟康唑更有效地实现真菌学清除。